Ewing Sarcoma Family of Tumors (ESFT): A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt

Sponsor

Assiut University (Other)

Overall Status

Completed

CT.gov ID

NCT04300179

Collaborator

(none)

Enrollment

Location

5.3

Actual Duration (Months)

11.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The aim of this study is to identify demographic & disease characteristics in pediatric oncology patients diagnosed with Ewing Sarcoma Family of Tumors (ESFT) & treatment outcomes in these patients.

Condition or Disease	Intervention/Treatment	Phase
Soft Tissue Neoplasms Bone Neoplasms Neoplasms

Detailed Description

Ewing sarcoma (ES) and peripheral primitive neuroectodermal tumor (PNET), Both entities that currently comprise the same spectrum of neoplastic diseases known as the Ewing sarcoma family of tumors (EFT), were originally described as distinct clinicopathologic entities. Primitive neuroectodermal tumors (PNETs) first described in 1918 by Stout as a malignant tumor arising from major nerve. Later, in 1921, ES was described as an undifferentiated tumor involving the diaphysis of long bones. It was also reported to arise in soft tissue (extraosseous ES). EFT is aggressive malignant small round cell tumors of bone and soft-tissue that predominantly affecting children and young adults.

Study Design

Study Type:

Observational

Actual Enrollment :

59 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

Ewing Sarcoma Family of Tumors (ESFT): A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt

Actual Study Start Date :

Jul 7, 2020

Actual Primary Completion Date :

Dec 16, 2020

Actual Study Completion Date :

Dec 16, 2020

Outcome Measures

Primary Outcome Measures

Overall survival (OS) [From date of treatment initiation until the date of death from any cause or patients censored at last follow up, whichever came first, assessed up to 60 months]
Participants will be retrospectively followed forward in time from the date of initiation of treatment till death from any cause, an expected average of 5 years
Event Free Survival (EFS) [From date of treatment initiation until the date of event from any cause or patients censored at last follow up, whichever came first, assessed up to 60 months]
Participants will be retrospectively followed forward in time from the date of initiation of treatment till occurrence of an event from any cause (tumor progression, relapse) or death, an expected average of 5 years

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A to 19 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients whose age less than 19 years. Patients diagnosed with Ewing Sarcoma Family of Tumors (ESFT).

Exclusion Criteria:

Patients whose age more than 19 years. Patients diagnosed with other bone & soft tissue neoplasms.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	South Egypt Cancer Institute	Assiut		Egypt

Sponsors and Collaborators

Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Ahmed Mohammed Morsy, MD, Lecturer of Pediatric Oncology, Assiut University

ClinicalTrials.gov Identifier:

NCT04300179

Other Study ID Numbers:

ESFT_Upp_Egypt

First Posted:

Mar 9, 2020

Last Update Posted:

Dec 17, 2020

Last Verified:

Dec 1, 2020

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Ahmed Mohammed Morsy, MD, Lecturer of Pediatric Oncology, Assiut University

Ewing's sarcoma (ES)

Peripheral primitive neuroectodermal tumor (PNET)

Additional relevant MeSH terms:

Soft Tissue Neoplasms

Study Results

No Results Posted as of Dec 17, 2020